Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML

Despite advances in the treatment of acute myeloid leukemia (AML), prognosis of AML patients is still dismal and better treatment options are required. B-cell Lymphoma 2 (BCL-2) homology domain 3 (BH3)-mimetics are emerging as a novel class of apoptosis-inducing agents that are currently being teste...

Descripción completa

Detalles Bibliográficos
Autores principales: Ewald, Larissa, Dittmann, Jessica, Vogler, Meike, Fulda, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892884/
https://www.ncbi.nlm.nih.gov/pubmed/31801941
http://dx.doi.org/10.1038/s41419-019-2156-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892884/
https://www.ncbi.nlm.nih.gov/pubmed/31801941
http://dx.doi.org/10.1038/s41419-019-2156-2

Ejemplares similares